Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Suliqua

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Croatia joins European medicines network

Follows country's membership of the European Union

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

European Commission hails progress on paediatric medicines

Says improvements made on both safety and research in Europe

- PMLiVE

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

ADA: Novo Nordisk steps up Lantus challenge with new Tresiba data

But still faces at least a three-year wait for US approval

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

Celgene wins expanded EU approval for cancer drug Revlimid

Approved for use in patients with rare blood disorder

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

FDA approves Sanofi’s four-in-one flu vaccine

But wants more safety data for hepatitis B vaccine from Dynavax

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links